Company profile: Omega Therapeutics
1.1 - Company Overview
Company description
- Provider of a proprietary epigenomic programming platform (OMEGA Platform) to develop therapeutics by controlling gene expression; conducts the MYCHELANGELO Phase 1/2 trial in non-small cell lung cancer; runs IND-enabling preclinical studies in inflammation/immunology and other diseases to assess gene targets; and offers an expanded access policy for investigational therapies.
Products and services
- OMEGA Platform: Proprietary epigenomic programming platform that engineers therapeutics by controlling gene expression, enabling development of therapy candidates
- IND-Enabling Studies: Preclinical program that assesses gene targets for early development in inflammation/immunology and other diseases, supporting advancement of therapeutic candidates
- MYCHELANGELO™ Study: Phase 1/2 clinical trial in non-small cell lung cancer, comprising early clinical evaluation stages for therapeutic development
Key contacts
🔒
🔒
Financial details
🔒
1.2 - Competitors and similar companies to Omega Therapeutics
Lakewood-Amedex
HQ: United States
Website
- Description: Provider of novel anti-infective therapeutics for serious infectious diseases, including Bisphosphocins, a novel class of antimicrobial agents effective against a wide range of bacteria and fungi, including antibiotic-resistant strains; and Nu-3 gel, a Bisphosphocin gel for treating infected diabetic foot ulcers, advancing into Phase 2 clinical trials.
- Rationale: This competitor operates in a highly similar market segment with overlapping features.
- Company type: Private company
- Employees: ●●●●●
- Total funding raised: $●●●m
- Backers: ●●●●●●●●●●
- Acquisitions: ●●
View full Lakewood-Amedex company profile →
InVivo Biotech Services
HQ: Germany
Website
- Description: Provider of contract manufacturing services for development and production of monoclonal antibodies and recombinant proteins. Offerings include antibody production from hybridomas (small to large scale), recombinant protein expression in bacterial and mammalian systems, non-GMP cell line development, research antibodies produced in HEK under serum-free conditions, and SARS‑CoV‑2 antigens and antibodies for immunoassays.
- Rationale: This competitor operates in a highly similar market segment with overlapping features.
- Company type: Private company
- Employees: ●●●●●
- Total funding raised: $●●●m
- Backers: ●●●●●●●●●●
- Acquisitions: ●●
View full InVivo Biotech Services company profile →
NeoPhore
HQ: United Kingdom
Website
- Description: Provider of novel small molecule cancer therapies that stimulate the immune system by targeting DNA mismatch repair to induce neoantigen expression and increase immunogenicity in solid tumors, including PMS2 and MLH1 modulators that convert immune-cold tumors to hot and enhance sensitivity to immune checkpoint inhibitors, plus continuous neoantigen creation and research and development on next-generation targets.
- Rationale: This competitor operates in a highly similar market segment with overlapping features.
- Company type: Private company
- Employees: ●●●●●
- Total funding raised: $●●●m
- Backers: ●●●●●●●●●●
- Acquisitions: ●●
View full NeoPhore company profile →
Interleukin Genetics
HQ: United States
Website
- Description: Provider of genetic tests for the emerging personalized health market, using applied genetics to empower individuals to personalize their health.
- Rationale: This competitor operates in a highly similar market segment with overlapping features.
- Company type: Private company
- Employees: ●●●●●
- Total funding raised: $●●●m
- Backers: ●●●●●●●●●●
- Acquisitions: ●●
View full Interleukin Genetics company profile →
Constellation Pharmaceuticals
HQ: United States
Website
- Description: Provider of novel therapeutics in the emerging field of epigenetics, focusing on selective regulators of epigenetic function critical to controlling gene expression; the first biopharmaceutical company dedicated to this area.
- Rationale: This competitor operates in a highly similar market segment with overlapping features.
- Company type: Private company
- Employees: ●●●●●
- Total funding raised: $●●●m
- Backers: ●●●●●●●●●●
- Acquisitions: ●●
View full Constellation Pharmaceuticals company profile →
🔒
2.M&A buyers
2.1 Potential strategic acquirers in the sector
🔒
🔒
🔒
🔒
View all strategic buyers with complete profiles
Start Free Trial →
2.2 - Strategic buyer groups for Omega Therapeutics
🔒
Buyer group 1: ████████ ████████
●● companies
Description: ████████ ████████ ████████ ████████ ████████ ████████ ████████ ████████ ████████ ████████
Key Products: ████████, ████████, ████████, ████████
🔒
View all companies in this group
Request Free Trial Now →
🔒
Buyer group 2: ████████ ████████
●● companies
Description: ████████ ████████ ████████ ████████ ████████ ████████ ████████ ████████ ████████ ████████
Key Products: ████████, ████████, ████████, ████████
🔒
View all companies in this group
Request Free Trial Now →
🔒
Buyer group 3: ████████ ████████
●● companies
Description: ████████ ████████ ████████ ████████ ████████ ████████ ████████ ████████ ████████ ████████
Key Products: ████████, ████████, ████████, ████████
🔒
View all companies in this group
Request Free Trial Now →
🔓 Unlock all detailed buyer group breakdowns with complete company profiles
Start Free Trial →
3. Investors and private equity firms
3.1 - Buyout funds investing in similar companies to Omega Therapeutics
2.2 - Growth funds investing in similar companies to Omega Therapeutics
🔒
View all growth equity funds with complete profiles
Start Free Trial →
4 - Top valuation comps for Omega Therapeutics
4.2 - Public trading comparable groups for Omega Therapeutics
🔓 Unlock all public trading comparable groups with complete valuation data
Start Free Trial →